about
Topical cyclosporine A therapy for dry eye syndromeP2Y2 receptor agonists for the treatment of dry eye disease: a reviewThe pathophysiology, diagnosis, and treatment of dry eye diseaseEfficacy and patient tolerability of travoprost BAK-free solution in patients with open-angle glaucoma and ocular hypertension.Image-guided evaluation and monitoring of treatment response in patients with dry eye disease.Individual and population benefits of daily aspirin therapy: a proposal for personalizing national guidelines.Prevalence and risk factors of dry eye syndrome in a United States veterans affairs populationAndrogen deficiency and dry eye syndrome in the aging malePost-LASIK dry eyeDry eye disease.Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial.Instrument development of the UNC Dry Eye Management Scale.Dry Eye Disease: Impact on Quality of Life and Vision.A review of quality of life measures in dry eye questionnairesPrevalence of dry eye syndrome after a three-year exposure to a clean roomA comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma.A Randomized, Controlled Treatment Trial of Eyelid-Warming Therapies in Meibomian Gland Dysfunction.Dry eye as a mucosal autoimmune disease.Chemokine receptors CCR6 and CXCR3 are necessary for CD4(+) T cell mediated ocular surface disease in experimental dry eye disease.The cost-effectiveness of the Argus II retinal prosthesis in Retinitis Pigmentosa patients.Cost-effectiveness analysis of HLA-B*5801 testing in preventing allopurinol-induced SJS/TEN in Thai populationDevelopment of a preference-based index from the National Eye Institute Visual Function Questionnaire-25.Tear dysfunction and the cornea: LXVIII Edward Jackson Memorial Lecture.Mesenchymal stem/stromal cells protect the ocular surface by suppressing inflammation in an experimental dry eye.Utility values among glaucoma patients: an impact on the quality of life.Impact of dry eye syndrome on vision-related quality of life.Dry Eye Following Phacoemulsification Surgery and its Relation to Associated Intraoperative Risk Factors.Annual direct cost of dry eye in Japan.Impact of dry eye on work productivityLongitudinal evidence on punctal plug use in an elderly populationNational Burden of Eye Diseases in Iran, 1990-2010; Findings from the Global Burden of Diseases Study 2010Ocular surface parameters in older male veterans.A novel fluorescent lipid probe for dry eye: retrieval by tear lipocalin in humansDry Eye Profiles in Patients with a Positive Elevated Surface Matrix Metalloproteinase 9 Point-of-Care Test Versus Negative Patients.A nonrandomized, open-label study to evaluate the effect of nasal stimulation on tear production in subjects with dry eye diseaseTime trade-off: one methodology, different methodsThe Effect of TNF-α Blocker HL036337 and Its Best Concentration to Inhibit Dry Eye InflammationComparison of two methods for composite score generation in dry eye syndromeUnderstanding the true burden of dry eye diseaseEtiology, prevalence, and treatment of dry eye disease.
P2860
Q24201139-50C1BFCA-6E9E-43DA-8A96-62911B395969Q24608339-6AFDE81E-9F1B-4A8B-A170-2CF23CBFCA40Q28083825-10DD8C7A-A879-4023-93D5-50D61B7F6207Q30435051-4BB04FB1-BD6B-465D-8657-1516BF3AED81Q33686417-F5077D2B-7D83-4580-B82D-1E359AD99D53Q33689688-21A176BA-CA2F-4FFA-92BB-FF7B4F6B5E3AQ33964406-5540C2F4-443A-4847-819C-0E3D7F7FD63DQ34043708-5BCCF3B8-4202-4C91-9602-7B8C75766170Q34102815-EB253D4A-4E28-4549-89BC-376CD3D86E83Q34123349-832C4720-71E0-45E1-8275-C4BCE20B1D38Q34206399-B53A7476-2D53-4968-B8E2-635E8DF0DFC9Q34302236-3F8DFD45-2B32-4A6D-A25F-C7807DF1A656Q34346990-2504C83B-CFA9-4409-AC38-57DE8D20B188Q34364536-31D054B7-AA11-4E0A-AA7C-7B3574148624Q34383016-CFDA7808-FF52-47A2-91D5-1DC7962307E0Q34386849-B40B05E2-7C3B-4F50-A162-66F6546497D5Q34627003-63CB103E-D858-4F6C-BA8F-5D5435484C1DQ34647761-810A2A6B-EB59-4D8D-8999-E39D1D30D9B5Q35040958-D49D5910-7A2D-4E4F-86E1-249D8414C45CQ35147398-26D3E4A6-FB68-4012-A370-A33D0DED7110Q35147703-F9F37546-B725-4950-9465-41D956B45731Q35170913-E1380219-73A7-4AE6-ADF5-D8C163ABD199Q35570793-8B2E3FCC-C99A-4DD0-9FCC-6115738B8496Q35591394-DB0C952F-3436-40E0-8A87-A90C6909DAC1Q35593716-8F64E0C3-18D4-4F5C-B3FA-F0BB272C3267Q35741609-8C4F0DE8-053B-4CFF-A87B-ECDD9696965FQ35875099-BBC668D6-7875-466D-AFD6-07A2CBB67C92Q35997499-2B6E78B3-D025-447C-A676-54CA0FD34BC3Q36317967-91FAF3E1-52AF-4253-B92B-E32B2781EBBCQ36469760-F67A98F7-9BE3-420C-A090-2B2690AB9CAFQ36596504-AF319AC4-55F1-47EB-8AEB-A3647E00065FQ36683576-266CDBA1-9170-4D2C-9B2E-5C8A884C2C0BQ36683616-C538D6AA-8AD6-4EE9-B0EC-CA663FFB82C3Q36829070-4CEA6ED7-E003-42C0-8279-5DD121EB6EB9Q36887538-09C89C19-02DD-4D06-88E4-24C3DD709533Q37057629-9DE8C0C2-D0D9-40E3-BDC1-A14F97B7177AQ37136884-2D4FB88C-4CAD-4D7F-BF3C-B62D425BE3DAQ37187277-BD3296A4-25F7-4C9C-B973-8BE3A8FF1651Q37210882-77DE7FA8-0A38-487C-A3B0-9A95698E5A80Q37288773-1FEA6021-DB39-4B66-AE17-294CB9E9B2F4
P2860
description
2003 nî lūn-bûn
@nan
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
2003年學術文章
@zh
2003年學術文章
@zh-hant
name
Utility assessment among patients with dry eye disease.
@en
Utility assessment among patients with dry eye disease.
@nl
type
label
Utility assessment among patients with dry eye disease.
@en
Utility assessment among patients with dry eye disease.
@nl
prefLabel
Utility assessment among patients with dry eye disease.
@en
Utility assessment among patients with dry eye disease.
@nl
P2093
P1433
P1476
Utility assessment among patients with dry eye disease.
@en
P2093
Gary Lebovics
Gordon Jacobsen
John G Walt
John J Doyle
Rhett M Schiffman
Walton Sumner
P304
P356
10.1016/S0161-6420(03)00462-7
P577
2003-07-01T00:00:00Z